The VP.S ENCORE® is an innovative medical device designed to revolutionize organ preservation techniques. It offers a promising solution to the global organ shortage crisis by providing an alternative to traditional preservation methods, such as ice-filled coolers and expensive technologies. With pending patents, the VP.S ENCORE® has garnered significant attention, particularly with its Breakthrough Device Designation from the FDA, received in 2021.

Though the VP.S ENCORE® is still pending FDA approval, its promise in revolutionizing organ preservation and transplantation is undeniable, offering hope for patients awaiting life-saving organ transplants worldwide.

Note: The VP.S ENCORE® device has not yet been approved by the FDA

Preclinical testing with ex vivo human and porcine organs revealed positive outcomes when comparing the VP.S ENCORE® device directly to the standard of care control device (ice cooler).

Assessments of tissue viability, including parameters such as lactate reduction, enhanced contractility, reduced inflammation, and cell death, were conducted to compare the performance of the VP.S ENCORE® device with that of the standard ice cooler method.

The preclinical findings indicate that the VP.S ENCORE® device demonstrated superior performance compared to the current standard of care in all tests evaluating tissue viability post-preservation

Ease of Use

The VP.S ENCORE® system comprises a single-use disposable component that functions with a non-blood, nutrient-rich solution (perfusate) readily accessible in transplant centers. Engineered to function in environments with temperatures of up to 40ºC and endure the pressures typical of passenger aircraft cabins, the system ensures reliability in diverse settings.In the event of device failure for any reason, it seamlessly transitions to the standard of care (static cooling) protocol.

Portable

The VP.S ENCORE® Device is engineered for convenient transportation, featuring an outer housing similar in size to carry-on luggage. In contrast, competing technologies that employ blood as the perfusate are bulky, often necessitating specialized transport vehicles.